Kidney Cancer, ESMO 2016
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Xiang X, Chen L, He J, Ma G, Li Y J Inflamm Res. 2022; 15:1147-1158.
PMID: 35210817 PMC: 8863339. DOI: 10.2147/JIR.S348628.
ZBTB7/miR-137 Autoregulatory Circuit Promotes the Progression of Renal Carcinoma.
Wang L, Li Q, Ye Z, Qiao B Oncol Res. 2018; 27(9):1007-1014.
PMID: 29673422 PMC: 7848413. DOI: 10.3727/096504018X15231148037228.
Rong H, He X, Wang L, He Y, Kang L, Jin T Oncotarget. 2017; 8(47):82078-82084.
PMID: 29137245 PMC: 5669871. DOI: 10.18632/oncotarget.18427.
References
1.
Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F
. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1814-23.
PMC: 5024539.
DOI: 10.1056/NEJMoa1510016.
View
2.
Choueiri T, Escudier B, Powles T, Tannir N, Mainwaring P, Rini B
. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016; 17(7):917-927.
DOI: 10.1016/S1470-2045(16)30107-3.
View
3.
Ravaud A, Motzer R, Pandha H, George D, Pantuck A, Patel A
. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med. 2016; 375(23):2246-2254.
DOI: 10.1056/NEJMoa1611406.
View
4.
Choueiri T, Halabi S, Sanford B, Hahn O, Michaelson M, Walsh M
. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017; 35(6):591-597.
PMC: 5455807.
DOI: 10.1200/JCO.2016.70.7398.
View